| Patient | Benny Leonard |
|---|---|
| Date of birth | 1896-04-07 |
| Identifiers | MRN HR-BX008-SYN-TD; SSN (made up) 000-08-4106 |
| Document date | 1946-06-30 |
| Author | Miriam Okafor-Rosenthal, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Seven-week review: home blood pressure, work and symptoms. [S]
Mr. Leonard returns seven weeks after intake. His home readings fell below 140/90 mmHg three weeks ago, and Dr. Okafor-Rosenthal cleared him by phone for full cards, as the cardiologist had advised. He has refereed four full cards since, drinking water between bouts, without breathlessness or chest tightness. His home readings over the past two weeks averaged 134/84 mmHg. He takes losartan-hydrochlorothiazide each morning and atorvastatin each evening without muscle aches, cough or lightheadedness. He walks briskly most mornings and eats less salted meat. [S]
| Element | Detail |
|---|---|
| Home blood pressure | Average 134/84 mmHg over two weeks |
| Work | Four full cards without symptoms |
| Kidney function | Creatinine 1.06 mg/dL, potassium 3.9 mmol/L |
| System | Result | Finding |
|---|---|---|
| Cardiovascular | Negative | No chest tightness, palpitations, fainting or ankle swelling |
| Respiratory | Negative | No breathlessness at work |
| Musculoskeletal | Negative | No muscle aches on atorvastatin |
3 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Losartan 50 mg with hydrochlorothiazide 12.5 mg, one tablet each morning | One tablet each morning | Oral route | 1946-05-12 to 1946-06-30 | completed | S |
| Losartan 100 mg with hydrochlorothiazide 25 mg, one tablet each morning | One tablet each morning; held from the sick visit; stopped at the preventive visit | Oral route | 1946-06-30 to 1946-07-28 | stopped | S |
| Atorvastatin 40 mg tablet, one each evening | One tablet each evening | Oral route | 1946-05-26 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1946-06-30 | Body height | 165 | cm | S |
| 1946-06-30 | Body weight | 74 | kg | S |
| 1946-06-30 | Body mass index (BMI) [Ratio] | 27.2 | kg/m2 | S |
| 1946-06-30 | Systolic blood pressure | 136 | mm[Hg] | S |
| 1946-06-30 | Diastolic blood pressure | 86 | mm[Hg] | S |
| 1946-06-30 | Heart rate | 72 | /min | S |
| 1946-06-30 | Respiratory rate | 14 | /min | S |
| 1946-06-30 | Body temperature | 36.6 | Cel | S |
| 1946-06-30 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1946-06-30 | Sodium [Moles/volume] in Serum or Plasma | 138 | mmol/L | 135-146 mmol/L | Normal | S |
| 1946-06-30 | Potassium [Moles/volume] in Serum or Plasma | 3.9 | mmol/L | 3.5-5.3 mmol/L | Normal | S |
| 1946-06-30 | Urea nitrogen [Mass/volume] in Serum or Plasma | 17 | mg/dL | 7-25 mg/dL | Normal | S |
| 1946-06-30 | Creatinine [Mass/volume] in Serum or Plasma | 1.06 | mg/dL | 0.7-1.3 mg/dL | Normal | S |
| 1946-06-30 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1941)/1.73 sq M | 84 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 1946-06-30 | Glucose [Mass/volume] in Serum or Plasma | 95 | mg/dL | 65-99 mg/dL | Normal | S |
Vital signs recorded on 1946-06-30; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; blood pressure 136/86 mmHg, pulse 72; weight 74.0 kg |
| Cardiovascular | Regular rhythm; fourth heart sound; no murmur; no edema |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Breathlessness and tightness across the chest on exertion for about two months, late in long nights of refereeing in hot arenas, easing within a few minutes of rest; never at rest; no fainting, palpitations, orthopnea or ankle swelling; cause under evaluation with a cardiology consultation | resolved | confirmed | R06.09 | S — Synthetic presenting problem anchored to his documented work as a referee; superseded at the consultation when stress testing showed no ischemia and the symptom was attributed to hypertensive heart disease. |
| Stage 2 hypertension found at a yearly fitness examination for his referee's license (164/100 and 160/98 mmHg), with left ventricular hypertrophy by voltage on the ECG; untreated; home readings to follow | resolved | confirmed | I10 | S — Synthetic diagnosis at intake; reclassified as hypertensive heart disease after the echocardiogram at the consultation. |
| Hypertensive heart disease without heart failure: concentric left ventricular hypertrophy (septum 13 mm, mass index 118 g/m2) with normal ejection fraction, grade 1 diastolic dysfunction, a mildly enlarged left atrium and an exaggerated blood pressure rise on exercise; no features of hypertrophic cardiomyopathy | active | confirmed | I11.9 | S — Synthetic diagnosis made at the cardiology consultation; not a claim about his real heart. |
| Coronary atherosclerosis found by coronary calcium scoring (Agatston score 186, about the 80th percentile for his age and sex), without angina and with no inducible ischemia on exercise stress echocardiography | active | confirmed | I25.10 | S — Synthetic diagnosis made at the cardiology consultation; not a retrospective diagnosis of the cause of his death, which is disputed. |
| Hypercholesterolemia: LDL 160 mg/dL, HDL 44 mg/dL, lipoprotein(a) not raised; no diabetes | active | confirmed | E78.00 | S — Synthetic diagnosis at intake. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Clinic blood pressure, average of two seated readings | Every visit | Completed today | 136/86 mmHg |
| Self-management | Home blood pressure monitoring (validated upper-arm cuff), readings sent weekly | Every day during titration; then a week before each visit | Completed today | Two-week average 134/84 mmHg |
| Laboratory | Basic metabolic panel (sodium, potassium, creatinine, eGFR) | Two to four weeks after starting or changing an ARB or diuretic; then every six months | Completed today | Sodium 138, potassium 3.9 mmol/L, creatinine 1.06 mg/dL, eGFR 84; repeat two weeks after today's increase |
| Laboratory | Lipid panel | Four to twelve weeks after starting a statin; then yearly | Due | At about nine weeks on atorvastatin |
| Examination | Symptoms: exertional chest discomfort, breathlessness, palpitations, fainting | Every visit | Completed today | None at four full cards |
| Imaging | Stress testing or coronary imaging | For new or changed exertional symptoms; not for routine surveillance | Not indicated | No new symptoms |
| Imaging | Echocardiogram | At diagnosis of stage 2 hypertension or suspected hypertrophy; repeat in six to twelve months to judge regression | Up to date | Repeat six to twelve months after the first |
| Examination | Weight, BMI and physical activity | Every visit | Completed today | 74.0 kg; brisk walks most mornings |
| Medication safety | Adherence and side effects (cough, edema, muscle aches, lightheadedness) | Every visit | Completed today | No missed doses; no cough, lightheadedness or muscle aches |
| Self-management | Return to work: refereeing, heat and hydration, warning symptoms, defibrillator at the venue | Before return to full exertion; then every visit | Completed today | Cleared for full cards three weeks ago; water between bouts |
| Self-management | Financial strain and medicine cost | Every visit | Completed today | Both medicines are generics he can afford |
Goal progress:
Guideline basis: 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults (2025); 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease (2023); 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia (2026); Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 6: Hypertension (2015); CMID: Clinical Monitoring Intelligence Database, hypertension, hyperlipidemia and ischemic heart disease monographs (2026)
Follow-up: Basic metabolic panel in two weeks. Preventive visit at the end of July with the lipid panel. Fifteen-week review in late August. Next scheduled visit 1946-07-28: periodic adult preventive visit and recheck after the sick visit. [S]